Phase 2
Completed N=165
Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution
Glaucoma, Open-Angle · Hypertension
Source: ClinicalTrials.gov NCT01001195 ↗
Enrolled (actual)
165
Serious AEs
0.6%
Results posted
Oct 2013
Primary outcomePrimary: Change From Baseline in Average Eye Intraocular Pressure (IOP) — 25.88; 25.18; 25.39; 25.73 Millimeters of Mercury (mmHg)
Summary
This study will evaluate the safety, efficacy and dose-response of AGN-210669. This study will also compare AGN-210669 with bimatoprost ophthalmic solution (LUMIGAN®).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline in Average Eye Intraocular Pressure (IOP) |
25.88; 25.18; 25.39; 25.73; -7.50; -7.65 | — |
Eligibility Criteria
Inclusion Criteria
- Ocular hypertension or primary open-angle glaucoma in each eye
- Patient requires IOP lowering medication in each eye
Exclusion Criteria
- Ocular hyperemia or other ocular surface findings in either eye
- Active ocular disease
- Current or anticipated use of any topical ocular medication (including artificial tears) during the study
- Intraocular surgery within past six months or unilateral cataract surgery.
- Functionally significant visual field loss
- Anticipated wearing of contact lenses during study
- Use of other medications that affect IOP such as glaucoma treating medications, within 2 months of screening visit
Data sourced from ClinicalTrials.gov (NCT01001195). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.